GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,708.60p
   
  • Change Today:
      3.40p
  • 52 Week High: 1,713.00
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 7,547,306
  • Market Cap: £70,819m
  • RiskGrade: 129

US green lights GSK vaccine for use during pregnancy

By Abigail Townsend

Date: Monday 10 Oct 2022

LONDON (ShareCast) - (Sharecast News) - GSK's whooping cough vaccine has been approved for use in pregnant women in the US.
Boosterix is already approved for use worldwide for immunisation against tetanus, diphtheria and pertussis, also known as whooping cough. But the US Food and Drug Administration has now approved it for use during the third trimester of pregnancy as well, to help prevent pertussis in babies under two months old.

GSK said the Centres for Disease Control and Prevention had reported between 15,000 to 48,000 cases of pertussis since 2010, with infants at a "high risk" of complications because of their immature immune systems.

Roger Connor, president of vaccines and global health at GSK, said: "We're immensely proud to have the first-ever Tdap vaccine approved by the FDA specifically for use during pregnancy.

"We believe this approval may help protect more infants from the potentially life-threatening implications of whooping cough."

GlaxoSmithKline was split into two companies earlier this year when it spun off its consumer healthcare division, called Haleon. The remaining business, rebranded GSK, is focused on prescription drugs and vaccines.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,708.60p
Change Today 3.40p
% Change 0.20 %
52 Week High 1,713.00
52 Week Low 1,316.00
Volume 7,547,306
Shares Issued 4,144.88m
Market Cap £70,819m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Price Trend
50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
17:14 750,000 @ 1,709.81p
17:04 13,917 @ 1,706.01p
17:04 13,076 @ 1,706.01p
17:04 549 @ 1,706.01p
17:03 172,458 @ 1,706.01p

GSK Key Personnel

CEO Emma Walmsley

Top of Page